MétaCan
Menu
Back to cohort
Record W2622353385 · doi:10.1002/hon.2438_80

MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE

2017· article· en· W2622353385 on OpenAlexaff
Christiane Pott, David Belada, Nathalie Danesi, Guenter Fingerle-Rowson, John G. Gribben, Chris Harbron, Eva Hoster, Brad S. Kahl, Britta Kehden, Kirsten Mundt, Emmanuelle Nicolas‐Virelizier, Laurie H. Sehn, Bruce D. Cheson

Bibliographic record

VenueHematological Oncology · 2017
Typearticle
Languageen
FieldMedicine
TopicChronic Lymphocytic Leukemia Research
Canadian institutionsUniversity of British ColumbiaBC Cancer Agency
Fundersnot available
KeywordsMedicineBendamustineInternal medicineMinimal residual diseaseObinutuzumabPopulationHazard ratioOncologyGastroenterologyFollicular lymphomaSurrogate endpointBone marrowLymphomaConfidence intervalRituximab

Abstract

fetched live from OpenAlex

Introduction: Minimal residual disease (MRD) response after first-line treatment of FL may predict outcome; however, data are limited in the relapsed/refractory (r/r) setting. We previously described MRD assessment in r/r FL in the randomised GADOLIN study (NCT01059630; Pott C, et al. ASH 2015). Here, we report updated results for MRD status for the full population. MRD kinetics post-induction with respect to treatment efficacy and prognosis are reported for the first time. Methods: Patients (pts) received obinutuzumab (G) + bendamustine (B) (90 mg/m2) followed by G maintenance, vs B (120 mg/m2) alone. MRD was analysed by t(14;18) real-time quantitative PCR (RQ-PCR) and/or allele-specific immune gene (IGH or IGK) RQ-PCR in pts with a clonal marker at diagnosis: at mid-induction (MI), end of induction (EOI) and 6-monthly intervals to 24 months post EOI/discontinuation. MRD status was negative (i.e. MRD response achieved) if RQ-PCR and subsequent nested PCR were negative. Results: Of 335 randomised pts with FL, a clonal marker was detected in 228/319 (71%) pts with baseline samples (baseline-evaluable population, BEP). Compared with the BEP, the population with a detectable marker was enriched for higher stage, worse FLIPI and bone marrow (BM) involvement. MI and EOI samples were analysed for 88 and 118 pts, respectively. MRD negativity in peripheral blood (PB) occurred early during induction and was more frequent with G + B: 41/52 (79%) pts were MRD negative at MI vs 17/36 (47%) in the B arm (p = 0.0029). At EOI, MRD responses further increased: 54/63 (86%) pts receiving G + B achieved MRD negativity in PB and/or BM vs 30/55 (55%) in the B arm (p = 0.0002) (Table). Pts with complete/partial response who were MRD negative at EOI had improved PFS and OS vs MRD-positive pts; hazard ratios (adjusted for treatment): PFS, 0.33 (95% CI 0.19–0.56, p < 0.0001), OS, 0.39 (95% CI 0.19–0.78, p = 0.008). Clinical outcome and MRD kinetics were highly impacted by post-induction treatment; MRD negativity was generally sustained with G maintenance, whereas MRD-negative pts in the B arm (no maintenance) converted back to MRD positivity and relapsed early (Figure). Conclusions: MRD status at EOI was a sensitive marker of treatment efficacy, demonstrating that adding G to B-based treatment significantly contributes to the speed and depth of response. MRD-negative pts after G + B appeared to benefit from G maintenance, which potentially preserved MRD negativity and helped to control lymphoma regrowth. Keywords: follicular lymphoma (FL); minimal residual disease (MRD); obinutuzumab.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.006
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.060
Threshold uncertainty score0.780

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.006
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.052
GPT teacher head0.389
Teacher spread0.337 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueHematological OncologySame topicChronic Lymphocytic Leukemia ResearchFrench-language works237,207